Nosopharm SAS
Natural products approach to antibiotic resistance
This article was originally published in Start Up
Executive Summary
Nosopharm SAS aims to address bacterial multidrug resistance to antibiotics, particularly in hospital-acquired gram-negative infections, using an-house drug discovery platform that exploits the microbial diversity of the bacterial genera Xenorhabdus and Photorhabdus.